Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two Department of Physiology, Anatomy and Genetics (DPAG) projects aimed at tackling heart failure are to be funded by the 2022 TCS London Marathon with the British Heart Foundation (BHF) as its Charity of the Year, as two of eight handpicked BHF projects.

Branching blood vessels in the heart © Joaquim Vieira

Nearly a million people in the UK are living with heart failure, often a long-term consequence of damage caused by a heart attack. After a heart attack, the heart often fails to form adequate new blood vessels to fully heal.

Associate Professor Sarah De Val and Dr Alice Neal have been studying the pathways regulating the formation and differentiation of vein and lymphatic vessel in both development, and after a heart attack or other tissue damage. Not only are venous and lymphatic endothelial cells crucial for the correct function of the circulatory system, they can also be used as building blocks for other types of vessels.

Dr Joaquim Vieira is studying cells of the epicardium, the outer layer of the heart, which are vital to normal heart development, including the growth and maturation of coronary blood vessels, the myocardial (heart muscle) layer and cardiac valves. If we can understand how epicardial cells contribute to these processes, we can better understand what goes wrong, not only in adult heart disease, but also in congenital heart disease in children.

Read the full story on the DPAG website

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.